Remission and relapse of autoimmune pancreatitis: Focusing on corticosteroid treatment

Hee Man Kim, Moon Jae Chung, Jae Bock Chung

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by swelling of the pancreas, narrowing of the main pancreatic duct, elevation of serum immunoglobulin G or G4 level or presence of several autoantibodies, or lymphoplasmacytic infiltration and fibrosis in the pancreas. However, the pathogenesis of AIP remains unclear, and the natural history and long-term prognosis of AIP are little known. Oral corticosteroid therapy for AIP is recommended. The absolute indications for steroid therapy for AIP are bile duct stenosis and accompanying systemic disease such as retroperitoneal fibrosis and diabetes mellitus. The dosage for remission induction is 30 to 40 mg/d for 1 to 2 months. The remission maintenance is needed to prevent relapse, and 5 to 10 mg/d for at least 6 months is recommended in patients who do not have complete remission. When relapse occurs, the dose used at remission induction can be readministered.Herein, we discuss remission and relapse of AIP, focusing on corticosteroid treatment to help clinicians care for patients with AIP and to help make an ideal treatment protocol of AIP through a review of published data. We tried to define remission and relapse of AIP to help investigate the natural course of AIP.

Original languageEnglish
Pages (from-to)555-560
Number of pages6
JournalPancreas
Volume39
Issue number5
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Pancreatitis
Adrenal Cortex Hormones
Recurrence
Therapeutics
Remission Induction
Pancreas
Retroperitoneal Fibrosis
Pancreatic Ducts
Chronic Pancreatitis
Clinical Protocols
Bile Ducts
Natural History
Autoantibodies
Patient Care
Diabetes Mellitus
Pathologic Constriction
Fibrosis
Immunoglobulin G
Steroids
Maintenance

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Kim, Hee Man ; Chung, Moon Jae ; Chung, Jae Bock. / Remission and relapse of autoimmune pancreatitis : Focusing on corticosteroid treatment. In: Pancreas. 2010 ; Vol. 39, No. 5. pp. 555-560.
@article{fd85cedeac0d4033b24dfa5ab0201fd0,
title = "Remission and relapse of autoimmune pancreatitis: Focusing on corticosteroid treatment",
abstract = "Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by swelling of the pancreas, narrowing of the main pancreatic duct, elevation of serum immunoglobulin G or G4 level or presence of several autoantibodies, or lymphoplasmacytic infiltration and fibrosis in the pancreas. However, the pathogenesis of AIP remains unclear, and the natural history and long-term prognosis of AIP are little known. Oral corticosteroid therapy for AIP is recommended. The absolute indications for steroid therapy for AIP are bile duct stenosis and accompanying systemic disease such as retroperitoneal fibrosis and diabetes mellitus. The dosage for remission induction is 30 to 40 mg/d for 1 to 2 months. The remission maintenance is needed to prevent relapse, and 5 to 10 mg/d for at least 6 months is recommended in patients who do not have complete remission. When relapse occurs, the dose used at remission induction can be readministered.Herein, we discuss remission and relapse of AIP, focusing on corticosteroid treatment to help clinicians care for patients with AIP and to help make an ideal treatment protocol of AIP through a review of published data. We tried to define remission and relapse of AIP to help investigate the natural course of AIP.",
author = "Kim, {Hee Man} and Chung, {Moon Jae} and Chung, {Jae Bock}",
year = "2010",
month = "7",
doi = "10.1097/MPA.0b013e3181c8b4a5",
language = "English",
volume = "39",
pages = "555--560",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Remission and relapse of autoimmune pancreatitis : Focusing on corticosteroid treatment. / Kim, Hee Man; Chung, Moon Jae; Chung, Jae Bock.

In: Pancreas, Vol. 39, No. 5, 07.2010, p. 555-560.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Remission and relapse of autoimmune pancreatitis

T2 - Focusing on corticosteroid treatment

AU - Kim, Hee Man

AU - Chung, Moon Jae

AU - Chung, Jae Bock

PY - 2010/7

Y1 - 2010/7

N2 - Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by swelling of the pancreas, narrowing of the main pancreatic duct, elevation of serum immunoglobulin G or G4 level or presence of several autoantibodies, or lymphoplasmacytic infiltration and fibrosis in the pancreas. However, the pathogenesis of AIP remains unclear, and the natural history and long-term prognosis of AIP are little known. Oral corticosteroid therapy for AIP is recommended. The absolute indications for steroid therapy for AIP are bile duct stenosis and accompanying systemic disease such as retroperitoneal fibrosis and diabetes mellitus. The dosage for remission induction is 30 to 40 mg/d for 1 to 2 months. The remission maintenance is needed to prevent relapse, and 5 to 10 mg/d for at least 6 months is recommended in patients who do not have complete remission. When relapse occurs, the dose used at remission induction can be readministered.Herein, we discuss remission and relapse of AIP, focusing on corticosteroid treatment to help clinicians care for patients with AIP and to help make an ideal treatment protocol of AIP through a review of published data. We tried to define remission and relapse of AIP to help investigate the natural course of AIP.

AB - Autoimmune pancreatitis (AIP) is a type of chronic pancreatitis characterized by swelling of the pancreas, narrowing of the main pancreatic duct, elevation of serum immunoglobulin G or G4 level or presence of several autoantibodies, or lymphoplasmacytic infiltration and fibrosis in the pancreas. However, the pathogenesis of AIP remains unclear, and the natural history and long-term prognosis of AIP are little known. Oral corticosteroid therapy for AIP is recommended. The absolute indications for steroid therapy for AIP are bile duct stenosis and accompanying systemic disease such as retroperitoneal fibrosis and diabetes mellitus. The dosage for remission induction is 30 to 40 mg/d for 1 to 2 months. The remission maintenance is needed to prevent relapse, and 5 to 10 mg/d for at least 6 months is recommended in patients who do not have complete remission. When relapse occurs, the dose used at remission induction can be readministered.Herein, we discuss remission and relapse of AIP, focusing on corticosteroid treatment to help clinicians care for patients with AIP and to help make an ideal treatment protocol of AIP through a review of published data. We tried to define remission and relapse of AIP to help investigate the natural course of AIP.

UR - http://www.scopus.com/inward/record.url?scp=77954115277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954115277&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181c8b4a5

DO - 10.1097/MPA.0b013e3181c8b4a5

M3 - Review article

C2 - 20182397

AN - SCOPUS:77954115277

VL - 39

SP - 555

EP - 560

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -